- Stocks
- Healthcare
- NASDAQ: FATE

Price (delayed)

$89.72

Market cap

$8.41B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.1

Enterprise value

$8.33B

The gross profit has surged by 194% year-on-year and by 71% since the previous quarter

FATE's revenue has surged by 194% year-on-year and by 71% since the previous quarter

The company's equity has surged by 57% YoY but it fell by 9% QoQ

The net income has plunged by 77% YoY and by 17% from the previous quarter

FATE's EPS is down by 46% year-on-year and by 14% since the previous quarter

What are the main financial stats of FATE

Market
Valuations
Earnings

Shares outstanding

93.78M

Market cap

$8.41B

Enterprise value

$8.33B

Price to earnings (P/E)

N/A

Price to book (P/B)

20.36

Price to sales (P/S)

235.15

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

264.97

Revenue

$31.43M

EBIT

-$173.39M

EBITDA

-$170.3M

Free cash flow

-$44.16M

Per share
Balance sheet
Liquidity

EPS

-$2.1

Free cash flow per share

-$0.54

Book value per share

$4.41

Revenue per share

$0.38

TBVPS

$7.56

Total assets

$622.46M

Total liabilities

$238.01M

Debt

$97.3M

Equity

$384.45M

Working capital

$408.76M

Debt to equity

0.25

Current ratio

5.78

Quick ratio

5.89

Net debt/EBITDA

0.5

Margins
Efficiency
Dividend

EBITDA margin

-541.8%

Gross margin

100%

Net margin

-551.6%

Operating margin

-407.5%

Return on assets

-31.2%

Return on equity

-46.2%

Return on invested capital

-55%

Return on capital employed

-32.3%

Return on sales

-551.6%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Fate Therapeutics stock price performed over time

Intraday

4%

1 week

-18.57%

1 month

0.46%

1 year

181.43%

YTD

-1.33%

QTD

-1.33%

How have Fate Therapeutics's revenue and profit performed over time

Revenue

$31.43M

Gross profit

$31.43M

Operating income

-$128.09M

Net income

-$173.39M

Gross margin

100%

Net margin

-551.6%

The gross profit has surged by 194% year-on-year and by 71% since the previous quarter

FATE's revenue has surged by 194% year-on-year and by 71% since the previous quarter

The net income has plunged by 77% YoY and by 17% from the previous quarter

The operating margin has soared by 57% YoY and by 40% from the previous quarter

What is Fate Therapeutics's growth rate over time

What is Fate Therapeutics stock price valuation

P/E

N/A

P/B

20.36

P/S

235.15

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

264.97

FATE's EPS is down by 46% year-on-year and by 14% since the previous quarter

FATE's price to book (P/B) is 94% higher than its last 4 quarters average of 10.5

The company's equity has surged by 57% YoY but it fell by 9% QoQ

FATE's revenue has surged by 194% year-on-year and by 71% since the previous quarter

The stock's price to sales (P/S) is 108% more than its 5-year quarterly average of 112.8 and 19% more than its last 4 quarters average of 198.3

How efficient is Fate Therapeutics business performance

FATE's return on sales is up by 39% year-on-year and by 32% since the previous quarter

The ROIC has grown by 31% YoY and by 6% from the previous quarter

Fate Therapeutics's return on assets has increased by 15% YoY

The ROE has grown by 7% YoY but it has contracted by 6% from the previous quarter

What is FATE's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for FATE.

How did Fate Therapeutics financials performed over time

FATE's total assets is 162% greater than its total liabilities

The company's quick ratio fell by 37% QoQ and by 26% YoY

FATE's current ratio is down by 37% from the previous quarter and by 29% YoY

The debt is 75% smaller than the equity

The company's debt to equity has surged by 127% YoY and by 25% QoQ

The company's equity has surged by 57% YoY but it fell by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.